GLP1RA drugs associated with behavioral side effects in type 2 diabetes and obesity

GLP1RA drugs associated with behavioral side effects in type 2 diabetes and obesity

Glucagon-like peptide 1 receptor agonists (GLP1RA) drugs for type 2 diabetes and obesity, which have recently been linked to behavioral side effects due to a surge in popularity as weight loss agents. A large population-based analysis inDiabetes, obesity and metabolism evaluated whether certain genetic variants could explain these effects.

GLP1RA mimics the GLP-1 hormone in the body, which helps control insulin and blood sugar levels and promotes satiety. GLP-1 bindsGLP1Ron cells in the brain and pancreas.

For the analysis, the researchers examined common genetic variants in theGLP1RGene in 408,774 White British, 50,314 White European, 7,667 South Asian, 10,437 Multiple-Ancestry and 7,641 African-Caribbean individuals.

Variants in theGLP1RGene had consistent associations with cardiometabolic traits (body mass index, blood pressure and type 2 diabetes) in terms of weight loss.GLP1RVariants were also associated with risk behavior, mood instability, chronic pain and anxiety in most atria, but results were less consistent. The genetic variants that influenced cardiometabolic traitsGLP1RGene.

The results suggest that any behavioral changes observed with GLP1RA are unlikely to occur directlyGLP1R.

Although it is not possible to directly compare genetic findings with the effects of a drug, our results suggest that behavioral changes are unlikely to be a direct result of GLPRA. Exactly how these indirect effects occur is currently unclear. “

Rona J. Strawbridge, PhD, corresponding author, University of Glasgow, UK

Sources: